Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

738

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Pneumonia
Interventions
DRUG

Avelox (Moxifloxacin, BAY12-8039)

Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)

DRUG

Levofloxacin + Ceftriaxone

Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).

Trial Locations (95)

1070

Bruxelles - Brussel

1200

Bruxelles - Brussel

2132

Johannesburg

3000

Leuven

4000

Liège

5000

Namur

7130

Somerset West

9300

Bloemfontein

10117

Berlin

11527

Athens

13353

Berlin

13616

Aix-en-Provence

14000

México, D.F.

14080

México, D.F.

18101

Afula

19002

Guadalajara

19100

Brive-la-Gaillarde

22004

Huesca

28008

Madrid

28805

Alcalá de Henares

31806

Saint-Gaudens

33000

Bordeaux

33098

Paderborn

39112

Magdeburg

44280

Guadalajara

44789

Bochum

44791

Bochum

45130

Kaunas

46014

Valencia

47144

Kaunas

47923

Agen

50130

Toluca

52621

Tel Litwinsky

58100

Holon

58515

Lüdenscheid

64239

Tel Aviv

64460

Monterrey

70014

Vesoul

75014

Paris

78306

Ashkelon

83056

Toulon

84000

Avignon

90016

Belfort

95107

Argenteuil

B1602DOH

Vicente López

C1118AAT

Buenos Aires

C1120AAF

Buenos Aires

C1180AAX

Buenos Aires

C1431FWO

Buenos Aires

Unknown

Temuco

Viña del Mar

Santiago

Bogotá

Bucaramanga

Bloemfontein

Cape Town

06112

Halle

265 04

Rio

546 36

Thessaloniki

LT-2001

Vilnius

LT-2006

Vilnius

02290

México, D.F.

07760

México, D.F.

5623 EJ

Eindhoven

5211 RB

's-Hertogenbosch

6716 RP

Ede

3844 DG

Harderwijk

6419 PC

Heerlen

02

Callao

01

Lima

LIMA 1

Lima Cercado

85-326

Bydgoszcz

80-803

Gdansk

30-501

Krakow

91-425

Lodz

00-909

Warsaw

01-138

Warsaw

50-417

Wroclaw

1769-001

Lisbon

0250

Brits

0083

Pretoria

08003

Barcelona

08036

Barcelona

08907

L'Hospitalet de Llobregat

551 85

Jönköping

391 85

Kalmar

651 85

Karlstad

541 85

Skövde

TS4 3BW

Middlesbrough

DG1 4EP

Dumfries

HU3 2JZ

Hull

EH4 2XU

Edinburgh

S60 2UD

Rotherham

S10 2JF

Sheffield

NE7 7DN

Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00431678 - Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia | Biotech Hunter | Biotech Hunter